Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 1,601–1,700 of 3,116
Kráľ, P., Holst‐Hansen, T., Olivieri, A., Ivanescu, C., Lamotte, M., & Larsen, S. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02932-8 · Cited by 3
Tentolouris, A., Siafarikas, C., Ntanasis‐Stathopoulos, I., Anastasiou, I. A., Kalara, E., & Briasoulis, Α. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.01.003 · Cited by 2
Ganeshalingam, A. A., Uhrenholt, N. G., Arnfred, S., Gæde, P., Pedersen, A. K., Bilenberg, N., & Frystyk, J. (2026) · Diabetes Care · doi:10.2337/dc25-2041 · Cited by 5
Semaglutide improves markers of cardiovascular risk in people with HIV
Lake, J. E., Kitch, D. W., Kantor, A., Alonso, C., Belaunzarán-Zamudio, P. F., Kulik, G. L., Hyatt, A. N., Fichtenbaum, C. J., Brown, T. T., LANDAY, A. L., et al. (2026) · AIDS · doi:10.1097/qad.0000000000004538 · Cited by 4
2025 Taiwan consensus recommendations for primary care of chronic kidney disease
Tsai, Y., Wu, P.-Y., Lai, T., Sung, C., Chiu, Y., Hwang, S., Hsu, Y., Wu, M.-S., & Shih, C. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.11.016 · Cited by 4
The Role of GLP-1 Receptor Agonists in Managing Cancer Therapy-Related Cardiac DysfunctionPreprint
Vignarajah, A., Kim, S., Albliwi, M., Ahn, H. M., Izda, A., Naffa, F., Vigneswaramoorthy, N. A., Barot, S. V., & Shah, G. V. (2025) · medRxiv · doi:10.1101/2025.01.02.25319923 · Cited by 2
López-Delgado, D. S., Narvaez, C. A., Gonzales, N. D. C., Martinez-Galaviz, R., Rivera‐Lozada, O., & Barboza, J. J. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238349 · Cited by 2
“New anti-obesity drugs (e.g., semaglu-tide, tirzepatide) achieve 15–20% weight loss and can reduce cardiovascular events, but they are best used as adjuncts to lifestyle therapy and, in selected cases, to surgery, rather than as stand-alone treatments [46,47].”
Infante, M., Ricordi, C., Pacifici, F., Pastore, D., Infante, R., Caprio, M., Chiereghin, F., Stefano, A. D., Frank, G., Rose, A. D., et al. (2026) · Nutrients · doi:10.3390/nu18132038 · Cited by 3
Oral Health Considerations and Dental Management Guidelines for Semaglutide Medications
Kofman, K., & Ouanounou, A. (2026) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2026.03.008 · Cited by 6
Kim, H. (2025) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2025.5.e4 · Cited by 2
Leite, A. R., Dias, J., Godinho, T., Correia-Chaves, J., Borges‐Canha, M., Lourenço, I. M., Leite-Moreira, A. F., & Neves, J. S. (2024) · Endocrinology Insights · doi:10.1159/000541442 · Cited by 5
Semaglutide cuts kidney risk in obesity
Giugliano, D., Nicola, L. D., Maiorino, M. I., & Esposito, K. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02494-0 · Cited by 2
Incretin‐Based Therapies for the Treatment of Binge Eating—A Systematic Review
White, R. T., Henriquez, P., Innocent, B., Bullers, K., & Elmaoued, A. A. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70135 · Cited by 2
Repetti, G. G., Abel, E. D., Tontonoz, P., & Sallam, T. (2026) · Circulation Research · doi:10.1161/circresaha.126.328680 · Cited by 3
Sleep and obesity—known interactions and open questions
Schmickl, C. N., Gomez, R., Sunwoo, B. Y., Mesarwi, O. A., Kumar, A., & Malhotra, A. (2026) · Journal of Clinical Sleep Medicine · doi:10.1007/s44470-026-00130-7 · Cited by 3
“Approximately half of OSA cases are attributable to excess body fat, [56, 57] representing a substantial population in whom weight reduction should be a central part of the treatment strategy as it promises broad health benefits beyond improvements in sleep-disordered breathing [24, 58].”
Human Papillomavirus as Nontraditional Cardiovascular Risk Factor: Fact or Fiction? Part 2
Palatnic, L., Kim, J. A., Kim, S. Y., Moras, E., Cagle-Colon, K. J., Kapp, D. S., & Krittanawong, C. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.07.014 · Cited by 2
Renke, G., & Chinellato, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093890 · Cited by 3
“In the SELECT study with obese non-diabetic patients, semaglutide reduced the incidence of major cardiovascular events (infarction, stroke) by ~20% at 5 years [33].”
Ostrominski, J. W., & Vaduganathan, M. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.07.002 · Cited by 2
Voetmann, L. M., Rolin, B., Kirk, R. K., Knudsen, L. B., Merkestein, M., Ahnfelt‐Rønne, J., Kodal, A. L. B., Jessen, C., Ozen, A. I., Pyke, C., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70510 · Cited by 3
“45,46 The GLP-1RA class of effective anti-diabetic and weight loss drugs has recently been shown to reduce the risk of cardiovascular events by 20% and similarly reduce the hsCRP by 39% (SELECT trial) 47 and 43.5% (STEP trial) 48 with an acceptable safety profile.”
InfluentialSeidel, D. U., & Bode, S. (2025) · HNO · doi:10.1007/s00106-025-01653-w · Cited by 4
Sedrak, P., Verma, R., Verma, M., & Connelly, K. A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.03.037 · Cited by 6
Byrne, J. P., Hinton, E. C., Humayun, M. A., Pournaras, D. J., Elsworth, R. L., Brunstrom, J. M., Hamilton-Shield, J. P., Sumeray, M. S., Easter, C., & Ashrafian, H. (2025) · Obesity · doi:10.1002/oby.70066 · Cited by 2
Beyond Weight Loss: Evaluating Cardiovascular Advantages of GLP-1 Receptor Agonists
Vezza, T., & Víctor, V. M. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00650-8 · Cited by 4
Kamarullah, W., Pranata, R., Wiramihardja, S., & Tiksnadi, B. B. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00695-9 · Cited by 3
Update to the Testosterone Guideline
Trost, L. W. (2024) · The Journal of Urology · doi:10.1097/ju.0000000000003855 · Cited by 3
Sex-specific Mendelian randomization phenome-wide association study of basal metabolic rate
Ng, J. C. M., & Schooling, C. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-98017-9 · Cited by 3
Vardhan, S., Arnott, C. G., Chen, A., Frolova, A. I., Meka, R. A., Raghuraman, N., Vijay, A., Yoo, S. G., & Mahmoud, Z. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101471 · Cited by 4
“These findings informed the design of SELECT, which followed non-diabetic patients with overweight or obesity and known CVD for 3 – 5 years, and reported 9.4 % mean weight loss and 20 % reduction in MACE compared to placebo [58].”
InfluentialCourtney, L. A., Clements, J. N., Isaacs, D. M., Pitlick, J. M., Reece, S. W., & Whitley, H. P. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103314 · Cited by 3
Cardiovascular effects of semaglutide and tirzepatide and their potential for cardioprevention
Cherkashin, D. V., Салухов, В. В., & Khalimov, Y. S. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-323 · Cited by 2
GLP-1 analogue therapy for obesity in people from Asia
Khoo, B. C. E., & Tan, T. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00031-7 · Cited by 2
Challenges in Modelling the Cost Effectiveness of Pharmacotherapies for Obesity
Pennington, B., Cummins, E., Chandler, A., & Fotheringham, J. (2025) · PharmacoEconomics · doi:10.1007/s40273-025-01520-0 · Cited by 4
Xiang, Y., Liu, Z., Feng, J.-K., Qin, Y., Yu, H., Cheng, Y., Chen, G., Wu, J., Huang, T., Tang, Y. C., et al. (2026) · Gut · doi:10.1136/gutjnl-2026-338462 · Cited by 4
Teli, B., Somani, S., Arya, V., Rajput, P. J., Kahale, P., Bharmal, V. S., Shah, S., Patel, V., Ahuja, A., & PATANGE, S. A. (2026) · Cureus · doi:10.7759/cureus.108999 · Cited by 2
“In subgroup analyses, the reduction in cardiovascular risk with semaglutide was most pronounced in the Asian population (hazard ratio {HR}: 0.64), followed by White individuals (HR: 0.81) and Black/African individuals (HR: 0.87) [29].”
InfluentialEmbracing an era of targeted combination therapy for heart failure with preserved ejection fraction
Shoji, S., Greene, S. J., & Mentz, R. J. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10432-8 · Cited by 3
Pharmacologic options for the treatment of overweight and obesity
Andrade, M. D. H. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002573 · Cited by 2
Watts, G. F., & Chan, D. C. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae095 · Cited by 2
Michalak, W., Zhao, Z., Faurby, M. D., Álvarez, S., & Fitch, A. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2526282 · Cited by 7
Toward a New SUMMIT in Heart Failure with Preserved Ejection Fraction
Felker, G. M. (2025) · New England Journal of Medicine · doi:10.1056/nejme2415551 · Cited by 2
Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy
Moura, F. A., Bellavia, A., Berg, D. D., Melloni, G. E. M., Feinberg, M. W., Leiter, L. A., Bohula, E. A., Morrow, D. A., Scirica, B. A., Wiviott, S. D., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15798 · Cited by 2
Cardiovascular-Kidney-Metabolic Health
Solomon, M., Claudel, S. E., & Verma, A. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2025.03.001 · Cited by 4
Dziewierz, A., & Siudak, Z. (2026) · Nutrients · doi:10.3390/nu18111761 · Cited by 3
“Furthermore, landmark trials such as SELECT have confirmed significant reductions in major adverse cardiovascular events (MACE), establishing these agents as systemic disease-modifying therapies beyond glycemic and weight control [7,14,15].”
Liu, L. Q., Mohan, S., & Wu, L. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf541 · Cited by 4
Options for patients with out-of-control blood pressure: after all avenues have been exhausted
Zeng, W., & Tomlinson, B. (2024) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2024.2401875 · Cited by 2
2024 Thai guidelines on the treatment of hypertension
Kunanon, S., Kotruchin, P., Chattranukulchai, P., Chotruangnapa, C., Roubsanthisuk, W., Vathesatogkit, P., Kunavisarut, T., Silaruks, S., Tejavanija, S., Wataganara, T., et al. (2025) · Asian Biomedicine · doi:10.2478/abm-2025-0034 · Cited by 3
“This often requires a more intensive approach of combining comprehensive lifestyle modifications, especially weight reduction, and titrated medication regimens [153, 160–172].”
Tsironikos, G. I., Tsolaki, V., Zakynthinos, G. Ε., Rammou, V., Kyprianidou, D., Antonogiannis, T., Zakynthinos, Ε., & Bargiota, Α. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70114 · Cited by 2
Kassab, J. T., Drazner, M. H., & Thibodeau, J. T. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag111 · Cited by 3
Dalpiaz, H., Masi, S., Piludu, S., Agnoletti, D., Piani, F., Fiorini, G., & Borghi, C. (2025) · Heart · doi:10.1136/heartjnl-2024-324847 · Cited by 4
Katsoulis, M., Leyrat, C., Hingorani, A. D., & Gomes, M. (2024) · Epidemiology · doi:10.1097/ede.0000000000001766 · Cited by 3
Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes
Abbasi, M., Sun, K., Huggins, K. W., Heath, B., DeLoit, H., McGinness, L., & Mccamy, K. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.035 · Cited by 10
“Semaglu-tide’s ability to promote significant weight loss of up to 15% in obesity trials and decrease cardiovascular risk highlights its dual benefit in T2D and long-term weight management 84,85 .”
Balata, M., Sugiura, A., Hassan, M. N. M., Rady, M., Christoph, M., Ibrahim, K. S. M. H., Becher, M. U., & Youssef, A. A. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02694-5 · Cited by 5
Peter, K., Roka, O., Sepp, E., Warburton, M., Zhang, J., & Cork, S. C. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00295-3 · Cited by 5
“In addition, post-hoc sensitivity analyses were performed by excluding the prediabetic population (SELECT trial [8]) in Fig.”
Oral Semaglutide and Cardiovascular Outcomes
Santos, M. C. F. D., de Lima, N. N., & Lima, J. G. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2508958 · Cited by 1
Malik, F., Shah, M., Chang, Y. K., Chowdhury, I. Z., Mangalesh, S., Morgan, A. A., Ezerioha, P., Modak, V., Lebovics, N., Adhikari, S., et al. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag044 · Cited by 2
Seijas‐Amigo, J., Salgado‐Barreira, Á., Eiras, S., Arias-Rivas, S., Rodríguez-Carnero, G., Rodríguez‐Mañero, M., & González‐Juanatey, J. R. (2026) · European Heart Journal Open · doi:10.1093/ehjopen/oeag101 · Cited by 2
“26 More recently, cardiovascular and metabolic outcome programmes involving oral GLP-1 receptor agonists have extended these findings beyond injectable formulations, reinforcing the potential cardiometabolic benefits of incretin-based therapies across different routes of administration.”
Cao, J., Jain, C. C., Egbe, A. C., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.043110 · Cited by 1
Rouleau, C. R., Moran, C., & Williamson, T. M. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.08.350 · Cited by 4
Endocrinology: What You May Have Missed in 2024
Aman, M., Jeevananthan, A., Martinez-Cruz, M., Namasingh, N., & Batch, B. C. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-00990 · Cited by 1
Hussain, M., & Miras, A. D. (2025) · Die Chirurgie · doi:10.1007/s00104-025-02402-z · Cited by 3
A New Era in the Medical Management of Obesity
Porterfield, F., Fatima, A., Boaventura, B. C. B., Madhar, A., Srivastava, G., & Stanford, F. C. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-125437 · Cited by 3
Vournas, G., Mourgos, L., Doumas, M. N., Liberopoulos, E. N., Kotsa, K., & Koufakis, T. (2026) · Diseases · doi:10.3390/diseases14020075 · Cited by 2
“Although GLP-1RA have demonstrated robust cardioprotective effects independent of glycemic control [19], the demographic and clinical characteristics of GLP-1RA users in this study do not suggest preferential allocation to patients with more advanced cardiovascular disease.”
Marston, N., Kany, S., Melloni, G. E. M., Jurgens, S. J., Kamanu, F., Lai, Y.-P., Rämö, J. T., Raz, I., Wiviott, S. D., Ellinor, P. T., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04439-x · Cited by 2
Deciphering the Effects of Semaglutide Across the Glycemic Spectrum
Misra, S. (2024) · Diabetes Care · doi:10.2337/dci24-0057 · Cited by 3
Varma, G., Murugadoss, K., Kurian, M. E., Varghese, J., Venkatakrishnan, A., & Soundararajan, V. (2026) · Biology Methods and Protocols · doi:10.1093/biomethods/bpag035 · Cited by 3
Petrescu, L., & Rachieru, C. (2025) · Romanian Journal of Cardiology · doi:10.2478/rjc-2025-0029 · Cited by 1
Bhatty, A., Wilkinson, C., Aktaa, S., Batra, G., Beska, B., Khaing, P. H., Wahab, A., Raveendera, K., Taha, A., Nadarajah, R., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5116096 · Cited by 1
Marzano, F., Paolillo, S., Gargiulo, P., Cotticelli, C., Santo, M. D., Nardi, E., Abbellito, G. M., Liccardi, L., Filardi, F. P., Bruzzese, D., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03215-y · Cited by 4
“Exclusion of the SELECT trial [5], only modestly weakened the statistical significance of the results (HR, 0.80; 95% CI, 0.64–1.00; p = 0.0478).”
InfluentialWolf, P. J. W., Correia, E. B., Neto, J. M. R., Finger, M. A., dos Santos, C. C., de Vasconcellos, M. A. B., Bruscky, L. V. R., Murta, A. C. D. S., Francisco, Y. A., Albrecht, F. C., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240676i · Cited by 1
The impact of GLP-1 analogues on cardiovascular risk
Kołakowska, K., Miłkowska, U., Piech, G. M., & Lis, I. (2024) · Biuletyn Głównej Biblioteki Lekarskiej · doi:10.2478/bgbl-2024-0030 · Cited by 1
Heart Failure with Preserved Ejection Fraction
Matthews, E. (2025) · AJN American Journal of Nursing · doi:10.1097/ajn.0000000000000184 · Cited by 3
Jaiswal, V., Mashkoor, Y., Borra, V., Gera, A., Patel, N., Jitta, S. R., NASIR, Y. M., Sharma, P., & Mattumpuram, J. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm45797 · Cited by 2
Goyal, A., Saeed, H., Jain, H., Hurjkaliani, S., Mahalwar, G., Jaiswal, V., Ricciardi, M. J., Kolte, D. S., Fonarow, G. C., Piazza, G., et al. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.04.003 · Cited by 4
Hypothalamic Gliosis is Associated With Multiple Cardiovascular Disease Risk FactorsPreprint
Lo, J., Melhorn, S. J., Kee, S., Olerich, K. L. W., Huang, A., Yeum, D., Beiser, A., Seshadri, S. S., DeCarli, C. S., & Schur, E. A. (2024) · medRxiv · doi:10.1101/2024.09.19.24313914 · Cited by 1
Maki, K. C., & Duell, P. B. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.01.008 · Cited by 1
Evidence-informed guidance for the clinical use of oral semaglutide in obesity management
Rubino, D., Wharton, S., Knight, M. G., & Aroda, V. R. (2026) · Postgraduate Medicine · doi:10.1080/00325481.2026.2686467 · Cited by 1
Zhong, Q., Xiong, Y., Zhu, Y., Ouyang, Q., Chen, X., Qin, F., Xu, F., An, K., Yu, B., & Qin, M. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114940 · Cited by 3
GLP-1 medications for weight-loss: a triumph of marketing over patient care
Chastain, R., Meadows, A., & Adams, L. (2026) · Fat Studies · doi:10.1080/21604851.2026.2646492 · Cited by 6
Huang, S. Y., Farber‐Eger, E. H., Tamaroff, J. G., et al. (2025) · medRxiv · doi:10.1101/2025.02.21.25322699 · Cited by 1
Fármacos basados en GLP-1: mecanismos implicados en el tratamiento de la obesidad
Salvador, J. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107035 · Cited by 13
A Sponsor’s Best Practice and Operating Principles to Manage Data Monitoring Committees
Birck, M. M., Rasmussen, J. S., Helmark, I. C., & Lollike, K. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-025-00742-w · Cited by 2
Hu, Y., Li, Z., Li, Z., Zhao, Y., Liu, Q., Li, Q., & Cheng, X. (2024) · Hepatology · doi:10.1097/hep.0000000000001033 · Cited by 3
Vest, A. R., & Deswal, A. M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102715 · Cited by 1
The approach to triglyceride levels in patients with coronary heart disease
Shani, I., & Elis, A. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.06.004 · Cited by 1
Obesity-Associated Cardiovascular Risk and Benefit From PCSK9 Inhibition
Kang, Y. M., Giugliano, R. P., KEECH, A. C., López, J. A. G., Monsalvo, M. L., Ohman, E. M., Ran, X., Murphy, S. A., Sabatine, M. S., & O’Donoghue, M. L. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.10.036 · Cited by 8
Glucagon-like Peptide 1 Receptor Agonists and Obesity Associated with Eating Disorders
Grave, R. D. (2024) · IJEDO · doi:10.32044/ijedo.2024.02 · Cited by 1
Anderson, B. J., Daele, D. J. V., Claussen, A. D., Tanenbaum, Z. G., & Owen, S. R. (2026) · Annals of Otology Rhinology & Laryngology · doi:10.1177/00034894261450724 · Cited by 1
“In its native state, GLP-1 is quickly degraded by Dipeptidyl peptidase-4, leading to short duration of action.”
Arena, R. A., & Arena, A. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.09.004 · Cited by 1
Algoritmo de diagnóstico y tratamiento del sobrepeso y obesidad 2025 de la redGDPS
Fernández, L. C., Pérez, J. S., Fernández, C. G., & Vela, N. S. (2025) · Diabetes práctica · doi:10.52102/diabet/pract.2025.2.art3 · Cited by 1
Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide
Giugliano, D., Esposito, K., & Nicola, L. D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15892 · Cited by 1
Research Status on the Effects of Obesity on Acute Pancreatitis
Tayier, D., Wang, K., Yuan, Y., & Yang, Z. (2025) · Obesity Reviews · doi:10.1111/obr.70007 · Cited by 2
GLP‐1RA use improves outcomes post partial nephrectomy in T2DM patients with RCC: A TriNetX study
Kwon, S. H., Wardrop, F., Gonzalez, D., Ryan, F., Khutsishvili, L., Turner, R., Deameh, M. G., & Whalen, M. J. (2026) · BJUI Compass · doi:10.1002/bco2.70169 · Cited by 2
Patient support during GLP‑1 arGLP‑1 therapy: practical solutions for cosmetologists
Akhmedbaeva, I. A., Kruglova, L. S., & Gryazeva, N. V. (2025) · Medical alphabet · doi:10.33667/2078-5631-2025-23-7-10 · Cited by 1
New directions in childhood obesity treatment – A path forward or wishful thinking?
Reilly, J. L., Arora, S., Chatman, K., Cooper, Z., & Hsia, D. S. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.05.010 · Cited by 1
Yeo, Y. H., San, B., Lim, G., Tan, M. C., Shanmugasundaram, M., Lee, J. Z., Abidov, A., Alsidawi, S., Yang, E., & Lee, K. S. S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70441 · Cited by 1
“35 Additionally, these therapies are primarily for patients with Type 2 diabetes, while many young adults have Type 1 diabetes.”
Perceptions and stigma of anti-obesity pharmacotherapy in adult Polish women
Witaszek, T., Kłoda, K., Mastalerz-Migas, A., & Babicki, M. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1687120 · Cited by 1
Müller-Wieland, D., McGuire, D. K., Lincoff, A. M., Buse, J. B., Mann, J. F. E., Inzucchi, S. E., Pop‐Busui, R., Mulvagh, S. L., Emerson, S. S., Poulter, N. R., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70752 · Cited by 1
Self-citationGLP-1 receptor agonists and heart failure: insights from human genetics
Emanuelsson, F., & Benn, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf1058 · Cited by 1
Hasanzad, M., Patrinos, G. P., Meybodi, H. R. A., Nikfar, S., & Larijani, B. A. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01493-5 · Cited by 1
Lower extremity arterial disease perspective: IUA consensus document on "LEAD management". Part 2
Antignani, P. L., Poredoš, P., Gastaldi, G., Spirkoska, A., & Mansilha, A. (2025) · International Angiology · doi:10.23736/s0392-9590.25.05344-1 · Cited by 1
Detrimental effects of conflicts of interest in GLP-1 therapy guidance
Agarwal, A., Vandvik, P. O., Delvaux, N., & Agoritsas, T. (2026) · BMJ · doi:10.1136/bmj-2026-527061 · Cited by 1
Krishnamoorthi, M. K., Sideris, K., Bhimaraj, A., & Drakos, S. G. (2024) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1443 · Cited by 2
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
